Please login to the form below

Not currently logged in
Email:
Password:

Bone Therapeutics strengthens clinical development team

Dr Miguel Forte joins the firm as chief medical officer

Dr Miguel ForteDr Miguel Forte has joined Belgium biotechnology company Bone Therapeutics as its new chief medical officer.

Forte arrives at Bone Therapeutics with over 20 years of industry experience, most recently as chief operating and medical officer at TxCell and before that as chair of the commercialisation committee at the International Society of Cellular Therapy (ISCT).

His career to date has also seen him hold positions such as vice president, global medical affairs at UCB, as well as senior positions at the European Medicines agency, Bristol-Myers Squibb and Abbott.

Forte said: “The company has an advanced clinical pipeline with promising products in clinical development and I am impressed with its progress to date.

“I look forward to working with the Bone Therapeutics team to realise the potential of its ground breaking products for the benefits of the patients.”

In his new role Forte will oversee the company’s clinical development strategy and the advancement of its products to the market.

Thomas Lienard, chief executive officer at Bone Therapeutics, said: “His vast expertise in cell therapy will be a strong asset to our company and will further drive the progress of Bone Therapeutics’ innovative pipeline.

“In addition to his specific experience with cell therapy products, Dr Forte has extensive experience in interacting with regulatory bodies and establishing strong relationships with investigators and key opinion leaders.”

22nd March 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics